⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
globenewswire.com
KYMR
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
globenewswire.com
KYMR
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
globenewswire.com
KYMR
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
prnewswire.com
KYMR
Europe CAR-T Therapies Market for Autoimmune Disorders: Trends, Growth, and Forecast to 2035 | 47.4% CAGR Signals a USD 1.25 Billion Opportunity as Clinical Pipelines Advance
globenewswire.com
AUTL
KYMR
NVS
SANA
JNJ
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
prnewswire.com
KYMR
Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research
prnewswire.com
ABBV
JNJ
AMGN
BMY
PFE
NVS
SNY
LLY
AZN
UCB
BIIB
VTRS
GILD
KYMR
Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer
globenewswire.com
KYMR
ALOT
KURA
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com
KYMR